Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04992312 · ClinicalTrials.gov registry record · Phase 1
A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT04992312 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 7 participants.
The verdict
NCT04992312, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of a study drug called nasal glucagon (Baqsimi) in pediatric participants with type 1 diabetes (T1D) aged 1 to less than 4 years. Blood tests will be performed to check how much nasal glucagon gets into the bloodstream. Blood sugar will also be measured to understand the effect of the drug on blood sugar levels. The study consists of a screening period up to 35 days before dosing, 1 day when a dose of nasal glucagon will be given and then 2 telephone follow up calls; first follow-up call on the day after the nasal glucagon was given and second call about one week after nasal glucagon was given. The study will last up to 9 days, not including the screening period.
Interventions
- DRUG Glucagon Nasal Powder [Baqsimi]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-03-24 |
| Est. Completion | 2023-11-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04992312
The ClinicalTrials.gov registry entry for NCT04992312 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Glucagon Nasal Powder [Baqsimi] is the first listed.
NCT04992312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04992312 about?
NCT04992312 is a clinical study titled "A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes". The main purpose of this study is to evaluate the safety and tolerability of a study drug called nasal glucagon (Baqsimi) in pediatric participants with type 1 diabetes (T1D) aged 1 to less than 4 years. Blood tests will be performed to check how much nasal glucagon gets into the bloodstream. Blood ...
What is the current status of trial NCT04992312?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2022-03-24. Estimated completion is 2023-11-05.
What interventions are being tested in trial NCT04992312?
The interventions under investigation include: Glucagon Nasal Powder [Baqsimi] (DRUG).
Who is sponsoring clinical trial NCT04992312?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.